lapatinib has been researched along with pd 173074 in 3 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (pd 173074) | Trials (pd 173074) | Recent Studies (post-2010) (pd 173074) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 160 | 0 | 106 |
| Protein | Taxonomy | lapatinib (IC50) | pd 173074 (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | 0.028 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.0217 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.028 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.19 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.013 | |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | 0.5337 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.0268 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.19 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.1325 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Gavine, P; Gu, Y; Liu, C; Liu, YJ; Lv, J; Ni, X; Qian, J; Qian, Z; Shen, D; Su, X; Sun, Y; Xu, Y; Yin, X; Zhan, P; Zhang, J; Zhang, T | 1 |
| Aburatani, H; Fukayama, M; Hoshino, H; Hosoya, Y; Ishikawa, S; Lefor, AK; Matsubara, D; Morishima, K; Niki, T; Saito, S; Sata, N; Ui, T; Yasuda, Y | 1 |
3 other study(ies) available for lapatinib and pd 173074
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Crizotinib; Female; Humans; Lapatinib; Male; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fibroblast Growth Factors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lapatinib; Molecular Sequence Data; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor | 2015 |